Savara (SVRA) Equity Ratio (2010 - 2026)
Savara (SVRA) reported Equity Ratio of 0.79 for Q1 2026, up 1.7% year-over-year from 0.78 in Q1 2025, and down 0.91% on a QoQ basis from 0.8 in Q4 2025.
Savara (SVRA) has 17 years of Equity Ratio data on file, last reported at 0.79 in Q1 2026.
- Quarterly Equity Ratio rose 1.7% year-over-year to 0.79 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.79 (up 1.7% YoY) and the FY2025 annual result came in at 0.8, changed 0.48% from the prior year.
- Equity Ratio declined to 0.79 in Q1 2026 per SVRA's latest filing, from 0.8 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.83 in Q3 2024 and bottomed at 0.0 in Q4 2022.
- The 5-year median for Equity Ratio is 0.78 (2025), against an average of 0.64.
- The widest annual swing landed in 2022, when Equity Ratio slumped 100.53%; it then surged 52870.08% in 2024.
- Tracing SVRA's Equity Ratio over 5 years: stood at 0.0 in 2022, then jumped by 64.74% to 0.0 in 2023, then surged by 52870.08% to 0.81 in 2024, then retreated by 0.48% to 0.8 in 2025, then dropped by 0.91% to 0.79 in 2026.
- Per Business Quant, the three latest SVRA Equity Ratio figures stand at 0.79 (Q1 2026), 0.8 (Q4 2025), and 0.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 0.04 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 0.42 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.73 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.77 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.21 |
| 10 | Savara | 1.30 Bn | 1.30 Bn | - | 0.79 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.79 |
| Dec 31, 2025 | 0.80 |
| Sep 30, 2025 | 0.00 |
| Jun 30, 2025 | 0.74 |
| Mar 31, 2025 | 0.78 |
| Dec 31, 2024 | 0.81 |
| Sep 30, 2024 | 0.83 |
| Jun 30, 2024 | 0.73 |
| Mar 31, 2024 | 0.77 |
| Dec 31, 2023 | 0.00 |
| Sep 30, 2023 | 0.80 |
| Jun 30, 2023 | 0.73 |
| Mar 31, 2023 | 0.76 |
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.79 |
| Jun 30, 2022 | 0.81 |
| Mar 31, 2022 | 0.82 |
| Dec 31, 2021 | 0.82 |
| Sep 30, 2021 | 0.83 |
| Jun 30, 2021 | 0.84 |
| Mar 31, 2021 | 0.84 |
| Dec 31, 2020 | 0.66 |
| Sep 30, 2020 | 0.70 |
| Jun 30, 2020 | 0.73 |
| Mar 31, 2020 | 0.73 |
| Dec 31, 2019 | 0.75 |
| Sep 30, 2019 | 0.76 |
| Jun 30, 2019 | 0.77 |
| Mar 31, 2019 | 0.69 |
| Dec 31, 2018 | 0.71 |
| Sep 30, 2018 | 0.76 |
| Jun 30, 2018 | 0.70 |
| Mar 31, 2018 | 0.73 |
| Dec 31, 2017 | 0.75 |
| Sep 30, 2017 | 0.63 |
| Jun 30, 2017 | 0.63 |
| Mar 31, 2017 | 0.31 |
| Dec 31, 2016 | -1.24 |
| Sep 30, 2016 | 0.33 |
| Jun 30, 2016 | 0.34 |
| Mar 31, 2016 | 0.41 |
| Dec 31, 2015 | -0.50 |
| Sep 30, 2015 | 0.53 |
| Jun 30, 2015 | 0.75 |
| Mar 31, 2015 | 0.80 |
| Dec 31, 2014 | -0.26 |
| Sep 30, 2014 | 0.81 |
| Jun 30, 2014 | 0.85 |
| Mar 31, 2014 | 0.85 |
| Dec 31, 2013 | 0.87 |
| Sep 30, 2013 | 0.89 |
| Jun 30, 2013 | 0.91 |
| Mar 31, 2013 | 0.86 |
| Dec 31, 2012 | 0.89 |
| Sep 30, 2012 | 0.90 |
| Jun 30, 2012 | 0.91 |
| Mar 31, 2012 | 0.92 |
| Dec 31, 2011 | 0.92 |
| Sep 30, 2011 | 0.93 |
| Jun 30, 2011 | 0.92 |
| Dec 31, 2010 | 0.94 |